Drew Moghanaki/LinkedIn
Jun 7, 2025, 12:39
Drew Moghanaki: SAFRON II Was a “SABR in Lieu of Systemic Therapy” Study for Lung Metastases
Drew Moghanaki, Chief Medical Officer at Respirati and Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at David Geffen School of Medicine at UCLA, shared a post on X:
“Prof. Shankar Siva reminds us that SAFRON II was a ‘SABR in lieu of systemic therapy’ study for patients with lung metastases at SABRCAN 2025.”
More posts featuring Drew Moghanaki.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 6, 2025, 19:13
Sep 6, 2025, 19:01
Sep 6, 2025, 18:05
Sep 6, 2025, 17:52
Sep 6, 2025, 17:48
Sep 6, 2025, 17:39
Sep 6, 2025, 17:28